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Abstract: Granulocyte-monocyte apheresis is a relatively new therapy that has been proposed, 
sometimes with controversial results, for the treatment of inflammatory bowel disease, particu-
larly ulcerative colitis. The aim of the present study was to perform a thorough review of the 
literature on the application of this type of treatment in ulcerative colitis and discuss the results, 
in order to provide an opinion on its use which is shared by the involved experts. The review 
of the literature was performed by searching PubMed with appropriate key words. The results 
obtained suggest that the major role for this treatment at this moment is for those patients with 
steroid dependency or with major contraindications to use of steroids. However, promising, 
albeit very preliminary, results have also been observed in steroid-naïve subjects, and this is of 
particular interest in consideration of the safety profile of this therapeutic method. As such, the 
Adacolumn may prove useful in specific subgroups of patients. Future phenotypic, genotypic, 
and molecular characterization of patients with inflammatory bowel disease might prove useful 
in defining better those subjects who might benefit most from this treatment modality.
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Introduction
The treatment of chronic inflammatory bowel disease (IBD) is always a challenge for 
gastroenterologists dealing with this type of condition.1,2 Indeed, the variability and 
complexity of the clinical picture, the possibility that other organs and systems may 
be involved, and the possible toxicity caused by drugs make both the diagnosis and 
treatment of this condition particularly complex. In recent years, considerable progress 
has been made, both in diagnostic techniques and in the range of therapeutic options 
available. However, with regard to the latter, it has been shown that greater treatment 
potential is often accompanied by an increased risk of adverse events.3,4
The development of granulocyte-monocyte apheresis (GMA)5 appears to be an 
innovative approach, comprising both treatment safety and therapeutic potential. The 
Adacolumn® is the most diffuse device of this type and consists of a column packed 
with cellulose acetate beads capable of adsorbing granulocytes and monocytes and 
through which the blood of the patients is run. Extremely positive results have been 
reported using this method for the treatment of ulcerative colitis in Japan,6–13 but 
results obtained in Europe and the US have been more contradictory.14–19 Nevertheless, 
a recent meta-analysis20 pooling data from seven randomized controlled trials 6,9,17,21–24 
clearly demonstrated the benefits of this method with respect to control treatments for 
the induction of remission or response at week 12. On the other hand, the only sham-
controlled randomized controlled trial, in a slightly to moderately ill population, did 
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not show a statistically significant difference between sham 
and active treatment.24
In this report, the current knowledge related to GMA 
in the treatment of IBD has been reviewed by means of an 
extensive research aimed at retrieving all papers regarding 
the clinical efficacy and safety of the Adacolumn in the treat-
ment of ulcerative colitis. This research was done by means 
of a Medline search using specific key words, including 
Medical Subjects Headings (MeSH) for papers published 
since 1995. Additional references were also obtained by hand 
searches and cross-referencing. In all, only abstracts  written 
in  English were retrieved. The most meaningful papers 
regarding other aspects of the treatment, ie, mechanism(s) of 
action, identification of ideal patient profile, and pharmaco-
economics were also retrieved and included in the analysis 
by the authors. Thus, on the basis of each author’s personal 
experience, an “expert opinion” on this therapeutic approach 
was drawn up.
Mechanism of action
The underlying mechanism of action in GMA comprises 
the selective removal of cell populations taking part in the 
induction and perpetuation of intestinal inflammation in 
IBD. GMA is highly selective for granulocytes, monocytes, 
and macrophages5 and, in accordance with this finding, it 
has been shown that the outflow from GMA columns has a 
low (40/60%) monocyte and granulocyte cell count, while 
the lymphocyte and erythrocyte populations are almost 
unchanged. Interestingly, a reduction of monocytes and 
granulocytes can also be seen in the colonic mucosa of 
patients who respond to treatment.25 In particular, a recent 
study reported that inflammatory CD14+CD16+ monocytes 
are considerably reduced after 10 sessions of GMA in ulcer-
ative colitis, as well as in Crohn’s disease.26
A marked reduction in proinflammatory cytokines 
also accompanies this effect, which is probably triggered 
by a dual mechanism of action, ie, by their direct adsorp-
tion on the column and via reactive immune regulation 
of nonabsorbed leukocytes.27 In fact, interleukin-6 mRNA 
and interleukin-8 mRNA return to normal levels following 
GMA.28 Moreover, the clinical efficacy of GMA in IBD 
appears to be associated with an increase in circulating T reg-
ulatory lymphocytes, with a higher expression of FoxP3 in 
CD4+ T cells29 and with a reduction of both myeloid and 
plasmocytoid dendritic populations.30 Generally speaking, 
several elements indicate that, in addition to removal of 
activated cells, a reactive immunomodulatory effect is one 
of the mechanisms of action of GMA.
Current evidence of efficacy  
in ulcerative colitis
Many experimental demonstrations of the efficacy of GMA in 
IBD have been derived from uncontrolled studies7,13–17,25,31–34 
performed in patients who do not respond to conventional 
pharmacological treatment. In this setting, the data are fairly 
homogeneous, showing favorable responses (remission or 
partial response) at percentages varying from 60% to 84% 
of patients treated. Treatment with GMA also appears to be 
more advantageous compared with extension or intensifica-
tion of conventional pharmacological treatment, which has 
involved steroids in most studies. In those papers, use of 
GMA has led to a rapid reduction in the steroid dose and/or 
withdrawal of steroid administration. Furthermore, GMA 
is associated with a good safety profile.20 Evaluation of 
efficacy has been primarily performed using clinical and/or 
biohumoral parameters, while the healing of the intestinal 
mucosa has rarely been taken into consideration. According 
to the very limited amount of data available, mucosal healing 
would appear to take place in about 25% of cases.35
In ulcerative colitis, the efficacy of GMA and leukocyte 
apheresis, the other apheresis technique currently used to 
treat IBD, appears to be comparable, with a slight advantage 
for GMA, as shown in a prospective study that compared the 
two methods.36 While bearing in mind the statistical limits 
associated with the small number of patients recruited in 
this study (39 patients), the clinical response for the two 
procedures was similar (72.2% for GMA versus 66.6% for 
leukocyte apheresis).
Due to the obvious difficulty of carrying out double-
blind randomized studies with inactive columns, results 
are available from only two studies of this type (one using 
leukocyte apheresis and one using GMA). In the leukocyte 
apheresis study, the response to active treatment was sig-
nificantly higher than in control subjects (80% versus 33%, 
respectively).37 Surprisingly, in the other study, carried out 
in more than 200 patients treated with GMA or an inac-
tive column,24 no significant difference was found (clinical 
response for 44% versus 39%, respectively). In spite of the 
theoretically adequate strength of the study, the large num-
ber of cases rejected during recruitment or lost to follow-up 
during the study, together with debatable inclusion criteria, 
have given rise to some doubts regarding the reliability of 
these results. Furthermore, a recent meta-analysis20 of the 
seven randomized, controlled studies performed using the 
Adacolumn, which also included the afore-mentioned sham-
controlled study,24 nevertheless demonstrated the greater 
efficacy of GMA in reducing clinical and endoscopic activity 
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in ulcerative colitis compared with comparator treatment.20 
Results in over 1000 patients treated in the previously men-
tioned uncontrolled cohorts would appear to support the 
efficacy of GMA further.
The suggestion that the efficacy of GMA would appear to 
continue beyond the actual treatment period, with a “carryover” 
effect, is certainly interesting, although controversial. A lower 
probability of recurrence in the 6–12 months following 
effective GMA than after pharmacological treatment was 
documented in other studies.18,20,39 This proved true also in 
one randomized study showing that GMA reduced the prob-
ability of relapse of the disease.23 This study, carried out in 
patients in remission but at a high risk of recurrence (patients 
with fecal calprotectin . 5 times the upper limit of normal), 
demonstrated the efficacy of preventive treatment with GMA. 
In fact, 67.7% of patients treated with conventional pharma-
cological treatment showed a relapse of the disease within 
6 months, while a preventive cycle of five sessions of GMA 
reduced the risk by more than half (27.6%).
Evidence of differing efficacy using 
different treatment schedules
The most commonly used GMA treatment schedule consists 
of one weekly session for 5 weeks. Each apheresis session 
lasts for 60 minutes and the volume of filtered blood amounts 
to 1800 mL each session. Alternative schedules have been 
proposed with the use of “intensive” GMA comprising two 
sessions per week for a total of 10 sessions, or “longer” 
GMA, ie, an increase in the duration of each session or 
in the total number of sessions. It is somewhat difficult to 
establish whether these latter approaches are more efficacious 
compared with standard treatment, given that the evidence 
available so far concerns only open studies, each with a 
limited number of cases.
In a study by Sakuraba et al, an intensive GMA program 
was found to be more efficacious than the conventional 
schedule in achieving remission (71% versus 54%), and was 
also achieved in a shorter time period (14.9 ± 9.5 days versus 
28.1 ± 16.9 days).40 An even more intensive treatment sched-
ule of daily GMA (five sessions in five consecutive days) has 
been reported, with favorable therapeutic results41 and good 
safety, so that this type of schedule is now used in several 
Japanese institutions. Therefore, a frequency-dependent or 
dose-dependent response is possible. On the other hand, the 
safety profile of the procedure remains unchanged when the 
frequency of the sessions is increased.
In another study, increasing the number of sessions was 
more effective in achieving remission in patients undergoing 
steroid treatment compared with an increase in the steroid 
dose.9 However, recent data from a large number of European 
steroid-dependent or steroid-resistant patients treated openly 
with either the classic or an extended procedure demonstrate 
comparable efficacy, as far as both achievement of  remission 
(40% versus 44%) and clinical response (59% versus 56%) 
are concerned.42 In both cases, the treatment was well tol-
erated without significant differences in the frequency of 
adverse events.
Use of a combined regimen of intensive extended aphere-
sis (two sessions per week for the first 3 weeks and one ses-
sion per week for another 8 weeks) in a study by Hanai et al 
in 70 patients, provided responses, as far as percentages are 
concerned, that were comparable with steroids administered 
intravenously (83% versus 65%).22 In particular, the GMA 
response appears to be slower but longer-lasting in time (the 
percentage of response at 2 weeks is 40% for GMA and 50% 
for steroids, respectively, whereas at 6 and 12 weeks, it is 
77% and 65%, respectively, and 82% and 61%, respectively). 
Prolonging the duration of each session to 90 minutes, 
together with an increase in the number of sessions (one per 
week for 10 weeks), appears to increase the percentage of 
remissions (83%) and to reduce the need for steroids.12
In conclusion, the data available on more intensive and/or 
extended use of GMA differ considerably and need to be 
confirmed in controlled studies. In the meantime, it would 
seem reasonable to adhere to the recommended treatment 
schedule of one session per week for 5 weeks.
Patient profiles for ideal  
treatment candidates
Treatment of ulcerative colitis is characterized by a well defined 
flow chart with the following sequence:  mesalazine (mild and 
moderate active disease and  maintenance  treatment); steroids 
(moderate to severe active  disease); and  immunosuppressants 
and biological treatment  (steroid-dependent and steroid-
resistant disease).
Severe forms of the disease are not a major priority indi-
cation for GMA treatment, because a very rapid response is 
needed in these cases, as will occur in many cases when using 
steroids and/or biological drugs. Negative evidence is present 
in the literature in support of this consideration.24
On the other hand, evaluation of GMA in 163 patients 
with mild to moderate ulcerative colitis, for whom simulta-
neous treatment with mesalazine and/or azathioprine40 was 
permitted, showed a high rate of clinical remission (62.4%). 
A randomized study17 even showed a trend in favour of 
GMA compared with steroids in mild to moderate forms 
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of the disease (90% versus 75% of remission-response, 
 respectively) with a reduction in side effects but with higher 
costs. In one single report, GMA appeared to be more 
 effective in steroid-naïve patients and patients treated with 
low doses and for a short time only, but the data must still be 
confirmed in larger and more homogeneous studies.43 Other 
possible predictors of response found in these studies are low 
steroid doses43 and high basal granulocyte levels.35
In this type of patient, GMA could be an alternative option 
to steroid treatment and become a first-line option in condi-
tions for which contraindications to the use of steroids are 
greater, eg, diabetes, high blood pressure, and glaucoma.
However, steroid resistance with mild to moderate activ-
ity or steroid dependence appear, at present, to be the main 
indications for GMA. As confirmation of this, in a Japanese 
post-marketing surveillance study of 697 patients treated at 
53 centers in the period 1999–2006, 489 patients were found 
to be resistant to conventional forms of treatment, espe-
cially steroids.34 This report confirmed, in a larger number 
of cases, the previous retrospective review of the first 100 
Scandinavian patients (which grouped together ulcerative 
colitis, Crohn’s disease, and indeterminate colitis), who were 
almost all steroid-resistant or steroid-dependent19 and the 
data contained in the Italian Registry (92% steroid-resistant/
steroid-dependent patients).44 Further, the duration of clinical 
response to GMA treatment, although differing in the various 
studies, would appear to be long enough to allow the delayed 
response of azathioprine to be reached, thus suggesting a 
possible role for GMA in bridge therapy as an alternative to 
infliximab. In addition, because GMA has no significant side 
effects (see Safety section), it could be preferable in patients 
with contraindications to biological treatment (intolerance 
to infliximab, carriers of specific antibodies, hepatitis B 
virus carriers, multidrug immunosuppression, or a history 
of tumors).
As far as its possible use in prolonging remission is 
concerned, the efficacy of GMA used monthly has also 
been reported in a small group of 10 patients.40 The possible 
role of GMA in preventing relapses in high-risk patients, 
identified by high levels of fecal calprotectin, was reported 
by Maiden et al.23 No comparative studies of treatment with 
biological drugs and GMA or associated treatment using the 
two methods are available.
Safety
GMA has been demonstrated to be very safe, with a low 
percentage of side effects. The first important study assessing 
the efficacy and safety profile of GMA in the treatment of 
active ulcerative colitis carried out in Japan at the end of the 
1990s6 reported side effects in only 8% of cases treated with 
apheresis compared with 43% of adverse events recorded in 
a group of patients treated with traditional drugs, ie, steroids 
and/or mesalazine.
Later studies confirmed this excellent safety profile. In 
fact, the percentage of side effects occurring with GMA in 
the main clinical trials ranged from 5% to 33%, with almost 
total absence of serious adverse events.7–12,16,17,24,45 The main 
adverse events reported were shivering, nausea, headaches, 
“flushing”, and fever. These problems can last a few min-
utes to a few hours. Use of painkillers before starting the 
procedure may prevent onset of headaches, while fever can 
easily be treated with common antipyretics.46 In extremely 
rare circumstances, infection of the upper airways16,24 has 
been reported. Some alterations in hematochemical tests, 
consisting of an increase in transaminases and leucopenia, 
have also been very rarely observed.34,47
However, in most cases, side effects have been mild 
to moderate, almost never requiring discontinuation of 
treatment. The excellent tolerability of GMA reported in 
clinical studies has also been confirmed in observational 
studies carried out in large numbers of unselected patients, 
reflecting the real use of GMA in daily clinical practice.19,34 
In particular, in the recent post-marketing surveillance study 
carried out in Japan, adverse events, including complications 
related to the procedure (eg, difficulty in finding venous 
access, difficulty in preventing coagulation in the apheresis 
system, difficulty in maintaining a suitable venous return) 
occurred in 2.3% of treatment sessions and in 8.18% of 
patients.34 The most frequent events were headache (1.58%) 
and fever (1.29%), but no serious adverse events were found. 
No statistically significant differences in the rate of side 
effects were found between patients undergoing few proce-
dures (fewer than five) and patients undergoing more than six 
treatments. A relatively higher rate of side effects occurred 
in women and in hospitalized patients (P , 0.05).
With regard to the Italian experience, the National 
Register of Therapeutic Apheresis (online at http://www.
aferesi.it) shows that almost 95% of GMA procedures 
(94.9%)  produced no adverse events, with headaches being 
reported in 3.9% of cases.44
GMA has also been used in the treatment of pediatric 
forms of IBD, in spite of the lack of data currently available. 
From the limited evidence so far, which mainly comes from 
Japan, the treatment has proved to be extremely safe also 
in this context.48–51 Recently, the results of some European 
studies have also been published, which confirm the safety 
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of GMA in the treatment of pediatric patients with IBD.52,53 
In particular, a small Spanish study of nine pediatric patients 
did not report any adverse events (either early or late), despite 
placement of a central venous catheter,52 while the most 
frequent side effects found in a larger study in Scandinavia 
(37 patients with chronic IBD), all slight and not long-lasting, 
were tiredness (reported in most children) and headache (in 
30% of subjects undergoing treatment).53
Pharmacoeconomics
GMA has proved to be an effective and safe procedure in 
the treatment of steroid-dependent and chronically active 
ulcerative colitis. The main limitations to its use lie in the 
relatively high cost compared with traditional forms of treat-
ment, and also in the need to carry out this treatment in a 
hospital environment. A recent Spanish pharmacoeconomic 
study, which evaluated GMA in patients suffering from 
steroid-dependent ulcerative colitis in terms of cost efficacy 
in comparison with traditional azathioprine treatment showed 
that the costs involved in the two different approaches were 
comparable.54
In fact, despite an increase in cost of €5377 per year per 
patient treated (€11,436 versus €6059), the higher response 
rate obtained using GMA (61% versus 38.5%) as well as 
reduction in side effects and need for surgery indicate that the 
cost required to obtain remission is not very different between 
the two types of treatment (€18,748 versus €15,738).
The results of a recent Scandinavian study, published 
at present only in abstract form, confirm that GMA can be 
considered to be a cost-effective treatment if compared with 
traditional treatment approaches, given that the increase 
in cost, calculated by quality-adjusted life-years gained 
(€55,426), is in keeping with that of treatments considered 
to be cost-effective.55
Unfortunately, no pharmacoeconomic study comparing 
all the treatment approaches used for steroid-dependent/
steroid-resistant forms of ulcerative colitis, including bio-
logical drugs, is available as yet. However, if we consider 
the high cost of this latter type of treatment, GMA may in 
comparison still prove to be economical. However, without 
the results of appropriate pharmacoeconomic studies, no final 
conclusions can be drawn on this issue at present.
Conclusion
According to published data, GMA is a useful technique 
among the various treatment options available for ulcer-
ative colitis. In this setting, GMA has been used primar-
ily in steroid-dependent or steroid-resistant patients. 
However, promising preliminary results have also been 
obtained in steroid-naïve patients or when GMA is used as 
an alternative treatment to steroids during the acute phases 
of the disease. Thus, on the basis of the available data, and 
also due to the fact that the treatment is still rather expensive, 
we believe that its current use should be restricted mainly 
to steroid-dependent or steroid-resistant patients. However, 
GMA should also be considered for those patients in whom 
standard treatment cannot be used, due to lack of efficacy, 
toxicity, or personal intolerance. These possible indications 
are also based on the safety profile of GMA, which has now 
been confirmed both in clinical trials and in post-marketing 
surveillance, and probably also by some pharmacoeco-
nomic data which do not appear to be particularly negative. 
Although some observations suggest that diversified GMA 
schedules (more intensive and prolonged treatment) may in 
some instances offer better results, it is advisable at present 
to adhere to traditional treatment schedules, with one ses-
sion per week for 5 weeks. We believe that, in the future, as 
long as research progresses towards an increasing recogni-
tion of specific disease patterns, it will become possible to 
select patient subgroups likely to respond better to specific 
therapeutic approaches, such as GMA.
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